Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer-A Review

• Published in: Cancers Vol. 14; no. 1; p. 38
• Main Authors: van Hattum, Jons W, de Ruiter, Ben-Max, Oddens, Jorg R, Hulshof, Maarten C C M, de Reijke, Theo M, Bins, Adriaan D
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.12.2021; MDPI
• Subjects: Antigens; Bladder cancer; Cancer therapies; Chemoradiotherapy; Chemotherapy; Clinical trials; Cytotoxicity; Immune checkpoint inhibitors; Immune system; Immunotherapy; Invasiveness; Lymphatic system; Medical prognosis; Metastases; Metastasis; Patients; Pelvis; Radiation therapy; Review; Survival; Tumor microenvironment; Tumors; Urothelial cancer; bladder cancer; bladder-sparing treatment; immune checkpoint inhibitors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14010038

Despite current treatment strategies, the 5-year overall survival of muscle-invasive bladder cancer (MIBC) is approximately 50%. Historically, radical cystectomy (RC) with neoadjuvant chemotherapy has been the first-choice treatment for this patient group. Recently, several studies have reported encouraging results of using immune checkpoint inhibitors (ICI) prior to RC. However, in recent years, bladder-sparing alternatives such as CRT have gained popularity. The effect of radiotherapy on the tumor microenvironment is an important rationale for combining CRT with ICI therapy. Worldwide, twelve immunochemoradiotherapy (iCRT) trials are ongoing. Each study employs a different chemotherapy and radiotherapy regimen and varies the timing of ICI administration concurrent to radiotherapy, adjuvant, or both. Five studies have presented (preliminary) results showing promising safety and short-term survival data. The first peer-reviewed publications are expected in the near future. The preclinical evidence and preliminary patient data demonstrate the potential of iCRT bladder-sparing treatment for bladder cancer.